TECX
Tectonic Therapeutic, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 57 | +6 | 7.73M | $265.79M | +9 | −3 |
| Q1 2026 | 53 | +3 | 7.56M | $233.65M | +10 | −7 |
| Q4 2025 | 50 | 0 | 8.28M | $172.63M | +1 | −1 |
| Q3 2025 | 14 | -1 | 5.97M | $93.62M | n/a | −1 |
| Q2 2025 | 12 | -1 | 5.17M | $102.64M | n/a | −1 |
| Q1 2025 | 10 | +6 | 971.81K | $17.19M | +6 | n/a |
| Q4 2024 | 4 | 0 | 181.96K | $8.40M | +1 | −1 |
| Q3 2024 | 3 | 0 | 144.81K | $4.39M | n/a | n/a |
| Q2 2024 | 3 | n/a | 134.61K | $2.22M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 89.03K | n/a | $1.47M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 31.03K | n/a | $511,252 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Two Sigma Investments ✦ | 14.54K | n/a | $239,556 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 110 holders, 13.75M shares, $410.16M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 43 sh · $1,570
Officer · 43 sh · $1,505
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology